{"entity":{"id":"nct06112704","kind":"trial","name":"HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors","aka":[],"tldr":"A phase 2 trial of HS-20093 in advanced solid tumours, run by Hansoh BioMedical R&D Company, now recruiting.","summary":"HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors is a phase 2 interventional study registered as NCT06112704 by Hansoh BioMedical R&D Company, with 220 participants planned, started 2024-02-06 and due to reach its primary completion in 2026-07-31. Interventions recorded: HS-20093.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06112704","url":"https://clinicaltrials.gov/study/NCT06112704"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["hs-20093"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06112704","phase":"2","setting":"A Phase 2, Open-label, Multi-center Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors (ARTEMIS-005)","sponsor":"Hansoh BioMedical R&D Company","enrolled":220,"outcomes":[]},"route":"/trials/nct06112704/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"hs-20093","kind":"drug","name":"HS-20093","route":"/drugs/hs-20093/"}]}}